2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
2022
Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal Of The American Geriatrics Society 2022, 70: 2330-2343. PMID: 35499667, PMCID: PMC9378524, DOI: 10.1111/jgs.17826.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaMRCC diagnosisCognitive impairmentCell carcinomaFive-year survival rateSEER-Medicare patientsMedicare Part D coveragePart D coverageMild cognitive impairmentMRCC patientsMRCC treatmentEligible patientsOlder patientsTreatment initiationKidney cancerAgent useOAA treatmentPatientsStage IVSurvival rateNew casesDiagnosisD diagnosisEvaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaNon-cancer controlsRenal cell carcinomaMRCC diagnosisMild cognitive impairmentCell carcinomaRisk factorsCognitive impairmentOlder adultsProportional hazards modelNew cancer treatmentsCohort entryOlder patientsSurgical therapyMAIN OUTCOMEExclusion criteriaAgent useDisease processHazards modelPatientsMedicare datasetCancer treatmentDiagnosisDementiaCarcinoma